Antidepressants and Incident Hypertension in Primary Care Patients

References

1. 1.↵
   1. Gillespie CD,
   2. Hurvitz KA

   ; Centers for Disease Control and Prevention. Prevalence of hypertension and controlled hypertension–United States, 2007–2010. MMWR Suppl 2013;62:144–8.

   OpenUrlPubMed
2. 2.↵
   1. Olfson M,
   2. Marcus SC

   . National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66:848–56.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Pratt LA,
   2. Brody DJ,
   3. Gu Q

   . Antidepressant use in persons aged 12 and over: United States, 2005–2008. NCHS Data Brief 2011;76:1–8.

   OpenUrlPubMed
4. 4.↵
   1. Meng L,
   2. Chen D,
   3. Yang Y,
   4. Zheng Y,
   5. Hui R

   . Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. J Hypertens 2012;30:842–51.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Licht CM,
   2. de Geus EJ,
   3. Seldenrijk A,
   4. et al

   . Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension 2009;53:631–8.

   OpenUrlCrossRef
6. 6.↵
   1. Spindelegger CJ,
   2. Papageorgiou K,
   3. Grohmann R,
   4. et al

   . Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010. Int J Neuropsychopharmacol 2014;181–9.
7. 7.↵
   1. Carvalho AF,
   2. Sharma MS,
   3. Brunoni AR,
   4. Vieta E,
   5. Fava GA

   . The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 2016;85:270–88.

   OpenUrl
8. 8.↵
   1. Warrington SJ,
   2. Padgham C,
   3. Lader M

   . The cardiovascular effects of antidepressants. Psychol Med Monogr Suppl 1989;16:i-iii, 1–40.

   OpenUrlPubMed
9. 9.↵
   1. Wong J,
   2. Motulsky A,
   3. Eguale T,
   4. Buckeridge DL,
   5. Abrahamowicz M,
   6. Tamblyn R

   . Treatment indications for antidepressants prescribed in primary care in Quebec, Canada, 2006–2015. JAMA 2016;315:2230–2.

   OpenUrlPubMed
10. 10.↵
    1. Brieler JA,
    2. Scherrer JF,
    3. Salas J

    . Differences in prescribing patterns for anxiety and depression between general internal medicine and family medicine. J Affect Disord 2015;172:153–8.

    OpenUrlPubMed
11. 11.↵
    1. Schoen MW,
    2. Salas J,
    3. Scherrer JF,
    4. Buckhold FR

    . Cholesterol treatment and changes in guidelines in an academic medical practice. Am J Med 2015;128:403–9.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Scherrer JF,
    2. Salas J,
    3. Brieler JA,
    4. Miller BJ,
    5. Meyer D,
    6. Schneider FD

    . Depression leads to incident vascular disease: evidence for the relevance to primary care. Fam Pract 2015;32:147–51.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Hooks-Anderson DR,
    2. Crannage EF,
    3. Salas J,
    4. Scherrer JF

    . Race and referral to diabetes education in primary care patients with prediabetes and diabetes. Diabetes Educ 2015;41:281–9.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Schoen M,
    2. Tabak R,
    3. Salas J,
    4. Scherrer JF,
    5. Buckhold F

    . Comparison of adherence to guideline-based cholesterol treatment goals in men versus women. Am J Cardiol 2016;117:48–53.

    OpenUrl
15. 15.↵
    1. Brieler JA,
    2. Lustman PJ,
    3. Scherrer JF,
    4. Salas J,
    5. Schneider FD

    . Antidepressant medication use and glycemic control in co-morbid type 2 diabetes and depression. Fam Pract 2016;33:30–6.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Devkota B,
    2. Salas J,
    3. Sayavong S,
    4. Scherrer JF

    . Use of an online patient portal and glucose control in primary care patients with diabetes. Popul Health Manag 2016;19:125–31.

    OpenUrlPubMed
17. 17.↵
    1. Manard W,
    2. Syberg K,
    3. Behera A,
    4. et al

    . Higher referrals for diabetes education in a medical home model of care. J Am Board Fam Med 2016;29:377–84.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Manard W,
    2. Scherrer JF,
    3. Salas J,
    4. Schneider FD

    . Patient portal use and blood pressure control in newly diagnosed hypertension. J Am Board Fam Med 2016;29:452–9.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Heiden-Rootes KM,
    2. Salas J,
    3. Scherrer JF,
    4. Schneider FD,
    5. Smith CW

    . Comparison of medical diagnoses among same-sex and opposite-sex-partnered patients. J Am Board Fam Med 2016;29:688–93.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Roblin DW

    . Validation of a neighborhood SES index in a managed care organization. Med Care 2013;51:e1–8.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Solberg LI,
    2. Engebretson KI,
    3. Sperl-Hillen JM,
    4. Hroscikoski MC,
    5. O'Connor PG

    . Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease and depression. Am J Med Qual 2006;21:238–45.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Frayne SM,
    2. Miller DR,
    3. Sharkansky EJ,
    4. et al

    . Using administrative data to identify mental illness: what approach is best? Am J Med Qual 2010;25:42–50.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Thase ME

    . Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502–8.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Derby MA,
    2. Zhang L,
    3. Chappell JC,
    4. et al

    . The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol 2007;49:384–93.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Allard P,
    2. Gram L,
    3. Timdahl K,
    4. Behnke K,
    5. Hanson M,
    6. Sogaard J

    . Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 2004;19:1123–30.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Clerc GE,
    2. Ruimy P,
    3. Verdeau-Palles J

    . A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9:139–43.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Dierick M,
    2. Ravizza L,
    3. Realini R,
    4. Martin A

    . A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57–71.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Prakash A,
    2. Lobo E,
    3. Kratochvil CJ,
    4. et al

    . An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. J Child Adolesc Psychopharmacol 2012;22:48–55.

    OpenUrlPubMed
29. 29.↵
    1. Mease PJ,
    2. Russell IJ,
    3. Kajdasz DK,
    4. et al

    . Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum 2010;39:454–64.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Strawn JR,
    2. Prakash A,
    3. Zhang Q,
    4. et al

    . A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry 2015;54:283–93.

    OpenUrl
31. 31.↵
    1. Arnold SE,
    2. Kahn RJ,
    3. Faldetta LL,
    4. Laing RA,
    5. McNair DM

    . Tricyclic antidepressants and peripheral anticholinergic activity. Psychopharmacology (Berl) 1981;74:325–8.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Smith WT,
    2. Glaudin V,
    3. Panagides J,
    4. Gilvary E

    . Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191–6.

    OpenUrlPubMedWeb of Science
33. 33.↵
    1. Walsh BT,
    2. Hadigan CM,
    3. Wong LM

    . Increased pulse and blood pressure associated with desipramine treatment of bulimia nervosa. J Clin Psychopharmacol 1992;12:163–8.

    OpenUrlPubMedWeb of Science
34. 34.↵
    1. Wester HA,
    2. Siegers CP

    . Cardiovascular effects of mianserin and amitriptyline in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1980;18:513–7.

    OpenUrlPubMed
35. 35.↵
    1. Wilens TE,
    2. Biederman J,
    3. Baldessarini RJ,
    4. et al

    . Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996;35:1491–501.

    OpenUrlCrossRefPubMedWeb of Science